Business Context and Reporting Period
Aclarion, Inc. (ACON), an emerging growth company incorporated in Delaware, filed this Form 8-K on August 12, 2024. The report details a material definitive agreement entered into on the same date regarding a private placement of common stock.
Key Financial Metrics
This filing reports a specific capital raise transaction rather than comprehensive periodic financial results. Key metrics from the transaction include:
- Shares Issued: 400,000 shares of Common Stock.
- Price Per Share: $0.29.
- Gross Proceeds: $116,000.
- Transaction Costs: No fees or commissions were paid to placement agents.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
The primary material change is the execution of a subscription agreement with an institutional investor. This transaction was conducted "at-the-market" under Nasdaq rules pursuant to the Company's Form 1-A Offering Statement, which was qualified on June 24, 2024. There are no other material changes to financial conditions or operations disclosed in this specific report.
Guidance, Outlook, and Risks
Future Capital Raising: The Company retains the ability to raise up to approximately $29.68 million in additional proceeds on the same terms under the existing Offering Statement. Any future sales will be disclosed via subsequent Prospectus Supplements.
Uncertainty: Management explicitly states that while they desire to consummate additional sales, there are currently no oral or written agreements to do so, and future sales cannot be guaranteed.
Risks: The filing highlights the uncertainty of future capital raises under the current offering framework.
Investor Verification Checklist
- Verify the current share count and dilution impact of the 400,000 shares issued.
- Confirm the status of the Form 1-A Offering Statement and the remaining capacity of approximately $29.68 million.
- Review recent 10-Q or 10-K filings for the Company's actual cash position and liquidity needs, as this 8-K does not provide those figures.
- Monitor for subsequent Prospectus Supplements to track any additional sales under the offering.